Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index and the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index both fell by 0.8%, while the CSI Biotechnology Theme Index decreased by 0.4%, and the CSI Innovative Drug Industry Index and the CSI 300 Pharmaceutical and Health Index both declined by 0.3% [1][10][16] - Despite the overall market decline, the Hang Seng Innovative Drug ETF (159316) saw a net subscription of 22 million units throughout the day, indicating strong investor interest [1] - According to Zhongtai Securities, the current innovative drug market differs from the 2019-2021 period, as the narrative around innovative drugs has transitioned into a phase of actual realization, with transaction amounts reaching new highs, reflecting a leap in China's innovative capabilities from "quantity" to "quality" [1][3] Group 2 - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index focuses on leading companies in the Hong Kong medical and health industry, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other health sectors [4] - The CSI Innovative Drug Industry Index tracks leading A-share innovative drug companies, consisting of no more than 50 stocks involved in innovative drug research and development [6] - The CSI 300 Pharmaceutical and Health Index covers leading companies in the A-share pharmaceutical and health sector, including chemical pharmaceuticals, medical services, and medical devices, representing various segments of the future health industry [14]